Research and Markets: Competitor Analysis: PTH Receptor Agonists Lists Company-Specific Pipelines of PTH Receptor Agonists

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/a9643e/competitor_analysi) has announced the addition of the "Competitor Analysis: PTH Receptor Agonists" report to their offering.

The present Competitive Intelligence Report about Parathyroid Hormone (PTH) Receptor Agonists or PTH Analogs provides a competitor evaluation in the field of R&D projects with analogs of PTH used to stimulate the PTH receptor for the treatment of osteoporosis or other bone-related diseases as of January 2009. PTH analogs are recombinant and synthetic peptides delivered by injection, inhalation, nasal, oral and transdermal administration. The report includes a compilation of current active projects in research and development of PTH receptor agonists.

In addition, the report lists company-specific pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on:

• Drug Codes
• Target / Mechanism of Action
• Class of Compound
• Company
• Product Category
• Indication
• R&D Stage and additional comments with a hyperlink leading to the source of information.

Key Topics Covered:

Index

• Pipeline of PTH Receptor Agonists
• Corporate PTH Receptor Agonist R&D Pipelines

Corporate PTH Receptor Agonist R&D Pipelines

• Aegis Therapeutics
• Altea Therapeutics
• Asahi Kasei Pharma
• Biodel
• Chugai Pharmaceutical Co.
• Cinnagen
• Eli Lilly
• Emisphere Technologies
• GlaxoSmithKline
• Kyowa Hakko Kirin
• Manhattan Pharmaceuticals
• MDRNA
• Novartis
• NPS Pharmaceuticals
• Nycomed
• Ossogen
• Proxima Concept
• Radius Health
• Ranbaxy
• Teijin
• TransPharma
• Unigene
• USV
• Virchow Biotech
• Zelos Therapeutics
• Zosano Pharma

For more information visit http://www.researchandmarkets.com/research/a9643e/competitor_analysi